<?xml version='1.0' encoding='utf-8'?>
<document id="19245299"><sentence text="In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates."><entity charOffset="49-60" id="DDI-PubMed.19245299.s1.e0" text="dalcetrapib" /></sentence><sentence text="The primary objective of this study was to investigate the drug-drug interaction potential of dalcetrapib on drugs metabolized via major cytochrome P450 (CYP) isoforms using both in vitro and clinical approaches"><entity charOffset="94-105" id="DDI-PubMed.19245299.s2.e0" text="dalcetrapib" /></sentence><sentence text=" A secondary objective was to investigate the safety and tolerability of dalcetrapib alone or co-administered either with a combination of five probe drugs or with rosiglitazone"><entity charOffset="164-177" id="DDI-PubMed.19245299.s3.e0" text="rosiglitazone" /></sentence><sentence text="" /><sentence text="Human liver microsomes and a panel of substrates for CYP enzymes were used to determine IC(50) for inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4" /><sentence text=" In addition, two drug-drug interaction studies were conducted in healthy males: dalcetrapib 900 mg plus the Cooperstown 5 + 1 drug cocktail, which includes substrates for CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and dalcetrapib 900 mg plus rosiglitazone, a substrate for CYP2C8"><entity charOffset="245-258" id="DDI-PubMed.19245299.s6.e0" text="rosiglitazone" /></sentence><sentence text=" Pharmacokinetic and safety parameters were assessed" /><sentence text="" /><sentence text="In vitro, dalcetrapib was inhibitory to all CYP enzymes tested" /><sentence text=" IC(50) values ranged from 1" /><sentence text="5 +/- 0" /><sentence text="1 microM for CYP2C8 to 82 +/- 4 microM for CYP2D6" /><sentence text=" Co-administration of dalcetrapib plus drug cocktail showed no clinically relevant effect of 900 mg dalcetrapib on activity of CYP1A2, CYP2C19, CYP2D6, CYP2C9, or CYP3A4 following repeated administration"><entity charOffset="100-111" id="DDI-PubMed.19245299.s13.e0" text="dalcetrapib" /></sentence><sentence text=" Co-administration of dalcetrapib plus rosiglitazone showed no clinically relevant effect of dalcetrapib 900 mg on activity of CYP2C8"><entity charOffset="39-52" id="DDI-PubMed.19245299.s14.e0" text="rosiglitazone" /><entity charOffset="93-104" id="DDI-PubMed.19245299.s14.e1" text="dalcetrapib" /><pair ddi="false" e1="DDI-PubMed.19245299.s14.e0" e2="DDI-PubMed.19245299.s14.e0" /><pair ddi="false" e1="DDI-PubMed.19245299.s14.e0" e2="DDI-PubMed.19245299.s14.e1" /></sentence><sentence text=" Dalcetrapib was generally well tolerated"><entity charOffset="1-12" id="DDI-PubMed.19245299.s15.e0" text="Dalcetrapib" /></sentence><sentence text="" /><sentence text="Although in vitro studies indicated that dalcetrapib inhibits CYP activity, two clinical studies showed no clinically relevant effect on any of the major CYP isoforms at a 900 mg dose, which is higher than the 600 mg dose being explored in phase III studies" /><sentence text=" Dalcetrapib was generally well tolerated in these studies"><entity charOffset="1-12" id="DDI-PubMed.19245299.s18.e0" text="Dalcetrapib" /></sentence><sentence text=" However, these studies were limited to a small number of healthy males; additional, larger studies are necessary to study its safety" /><sentence text="" /></document>